Skip to main content

Table 1 Baseline liver characteristics including CT indices of steatosis and liver function tests

From: Baseline liver steatosis has no impact on liver metastases and overall survival in rectal cancer patients

 

No Liver Steatosis (n = 193; 68.2%)

Mild liver steatosis

(n = 71; 25.1%)

Moderate/Severe liver steatosis

(n = 19; 6.7%)

Liver density (HU); mean (SD)

58.35 (5.98)

49.38 (5.31)

34.84 (10.20)

Liver-to-spleen density ratio; median (range)

1.25 (1.09; 2.1)

1.09 (0.89;1.47)

0.78 (0.21; 1.03)

Liver-spleen density difference (HU); median (range)

12 (5; 33)

3.54 (−6; 15)

−10.53 (−38; 1)

AST (U/L); median (range) a

17 (10; 124)

25.57 (16; 48)

22.46 (7; 118)

AST > 40 U/L; n (%) a

3 (2.7)

4 (6.6)

1 (7.1)

ALT (U/L); median (range) a

14 (7; 94)

22.11 (7; 143)

30.29 (8; 76)

ALT > 49 U/L; n (%) a

2 (1.8)

2 (3.2)

2 (14.3)

GGT (U/L); median (range) a

17 (6; 280)

55.95 (7; 763)

49.21 (13; 171)

GGT > 73 U/L; n (%) a

4 (4.0)

9 (16.4)

3 (21.4)

  1. CT liver characteristics and liver function tests in patients with and without CT-defined liver steatosis. SD standard deviation, HU Hounsfield Units. a missing values were: in no liver steatosis group 83, 81, and 92 for AST, ALT, and GGT, respectively, in mild steatosis group 10, 9, and 16 for AST, ALT, and GGT, respectively, and in moderate/severe steatosis group 5 for all the three liver function tests.
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us